Last updated: February 19, 2026
What is Eurasian Patent EA033323?
Eurasian Patent EA033323, granted to Bayer Intellectual Property GmbH, covers "IMIDAZOPYRIDINE DERIVATIVES AS ILT3 INHIBITORS". The patent application was filed on October 25, 2018, and granted on May 31, 2021. The subject matter pertains to novel imidazopyridine compounds and their use in treating conditions mediated by ILT3 (Immunoglobulin-like Transcript 3). ILT3 is a transmembrane receptor expressed on myeloid cells and is implicated in immune regulation. Inhibiting ILT3 is proposed to modulate immune responses, suggesting therapeutic applications in inflammatory diseases, autoimmune disorders, and potentially cancer.
What Specific Inventions are Claimed?
The patent encompasses several claims related to the chemical structures of the imidazopyridine derivatives, their synthesis, and their therapeutic applications.
Compound Claims
The core of the patent lies in its composition of matter claims, defining specific chemical structures.
-
Claim 1: This claim defines a genus of imidazopyridine derivatives with a specific general formula. This general formula incorporates various substituents at defined positions on the imidazopyridine core, allowing for a broad range of potential compounds.
- The imidazopyridine core is substituted at specific positions (e.g., R1, R2, R3, R4).
- The substituents (R1-R4) include various functional groups such as alkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and substituted aryl groups, as well as various linking groups.
- This broad scope is typical for early-stage patent filings to capture a wide chemical space around a novel scaffold.
-
Dependent Claims (e.g., Claims 2-10): These claims narrow down the scope of Claim 1 by specifying particular embodiments of the general formula. They define more precise combinations of substituents, leading to specific compounds that have been synthesized and potentially tested. Examples of limitations in these dependent claims include:
- Specific definitions for R1, R2, R3, and R4, such as R1 being a substituted phenyl ring.
- Specific examples of heterocyclic or aryl groups that can be incorporated.
- The presence of particular atoms or functional groups at defined locations.
Method of Synthesis Claims
The patent also claims methods for preparing these imidazopyridine derivatives.
- Claims related to Synthesis: These claims describe the chemical reactions and processes used to synthesize the claimed compounds. This is crucial for ensuring that the invention can be practically manufactured. The claims typically cover:
- Key synthetic steps, including coupling reactions, cyclizations, and functional group transformations.
- Specific reagents and reaction conditions employed.
- Intermediate compounds formed during the synthesis.
Method of Use Claims
A significant portion of the claims focuses on the therapeutic applications of the claimed compounds.
- Claims 11-15: These claims cover the use of the claimed imidazopyridine derivatives for treating various medical conditions.
- Method of treating a disease: This claim typically involves administering a therapeutically effective amount of a compound of the general formula defined in Claim 1, or a specific compound defined in dependent claims, to a subject in need thereof.
- Diseases targeted: The patent specifies that these compounds are useful for treating diseases or conditions mediated by ILT3. This includes:
- Inflammatory diseases (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease).
- Autoimmune diseases (e.g., lupus erythematosus, multiple sclerosis).
- Conditions involving aberrant immune responses.
- Potentially, cancer, by modulating the tumor microenvironment.
- Pharmaceutical compositions: Claims may also cover pharmaceutical compositions comprising the active compound along with pharmaceutically acceptable carriers, diluents, or excipients.
What is the Intellectual Property Landscape for ILT3 Inhibitors?
The patent landscape for ILT3 inhibitors is evolving, with several pharmaceutical companies actively researching and developing therapies targeting this pathway. EA033323 contributes to this landscape by introducing a specific class of compounds.
Key Players and Competitors
- Bayer Intellectual Property GmbH: As the assignee of EA033323, Bayer is a primary player in this specific chemical space. Their R&D efforts are likely focused on developing drug candidates based on these imidazopyridine derivatives.
- Other Major Pharmaceutical Companies: Numerous other pharmaceutical giants and smaller biotechs are investigating ILT3 inhibition. These include, but are not limited to:
- Gilead Sciences, Inc.: Known for its work in immunology and inflammation, Gilead has research programs that may overlap with ILT3 inhibition.
- Bristol Myers Squibb Company: With a strong portfolio in autoimmune diseases and oncology, BMS is a potential competitor.
- Merck & Co., Inc.: Explores various immunological targets for therapeutic intervention.
- AbbVie Inc.: Actively develops treatments for inflammatory and autoimmune conditions.
- Genentech (a member of the Roche Group): A leader in biotechnology, with a broad focus on immunology and oncology.
- Biotechnology Companies: Smaller, specialized biotech firms are also active in developing novel immunomodulatory agents, potentially targeting ILT3 or related pathways.
Overlapping Patent Areas
The patent landscape is characterized by overlapping claims in several areas:
- Novel Compound Structures: Patents often claim specific chemical entities, but the general structures can overlap. Companies file patents to protect distinct chemical scaffolds or modifications thereof.
- Methods of Synthesis: While core synthetic routes might be patented, alternative or improved synthesis methods can be independently patented.
- Therapeutic Applications: Patents claiming the use of ILT3 inhibitors for specific diseases are common. However, the scope of "diseases mediated by ILT3" can be broad, leading to potential disputes over specific indications.
- Mechanism of Action: Patents may also claim the specific mechanism by which an ILT3 inhibitor operates, especially if it involves novel pathways or interactions.
Key Technologies and Targets within the ILT3 Field
The development of ILT3 inhibitors involves several key technologies:
- Small Molecule Inhibitors: EA033323 falls into this category, focusing on small organic molecules designed to bind to and inhibit the ILT3 receptor. This is a well-established approach in drug discovery.
- Antibody-Based Therapies: Antibodies, including monoclonal antibodies, are another significant class of ILT3 inhibitors. These can be designed to block ligand binding or to induce receptor internalization and degradation. Companies like Incyte Corporation have been active in developing ILT3-targeting antibodies [1].
- Immunomodulatory Drugs: The broader field encompasses agents that modulate the immune system. ILT3 inhibition is one strategy within this larger therapeutic area.
- Diagnostic Tools: Development of companion diagnostics to identify patients who would benefit most from ILT3-targeted therapies is also an emerging area.
Patent Strategy and Potential Challenges
The strategy behind filing patents like EA033323 is to secure market exclusivity for novel therapeutic agents. This typically involves:
- Broad Initial Claims: To capture a wide range of potential drug candidates within a specific chemical class.
- Narrowing Claims with Specific Examples: To cover concrete compounds that have been synthesized and tested, providing stronger evidence of utility and novelty.
- Securing Claims for Use: To protect the therapeutic applications and market potential of the invention.
Potential challenges in this patent landscape include:
- Prior Art: The existence of earlier patents or publications disclosing similar chemical structures or therapeutic uses could invalidate or limit the scope of EA033323. A thorough prior art search is essential for any company operating in this space.
- Freedom to Operate (FTO): Companies developing their own ILT3 inhibitors must conduct FTO analyses to ensure their activities do not infringe on existing patents, including EA033323.
- Patent Opposition and Litigation: Patents can be challenged through opposition proceedings or litigation if competitors believe they are invalid or infringed.
- Evolving Scientific Understanding: As research progresses, the understanding of ILT3's role in various diseases may evolve, potentially impacting the perceived utility and enforceability of related patents.
Analysis of EA033323's Strategic Position
Eurasian Patent EA033323, by Bayer Intellectual Property GmbH, positions the company within the competitive field of ILT3 inhibition. The patent's strength lies in its broad composition of matter claims for imidazopyridine derivatives, which provides a foundation for a pipeline of potential drug candidates. The inclusion of method of use claims further solidifies its market protection potential for specific therapeutic indications.
The geographical scope of the Eurasian Patent Organization is significant, covering numerous member states that represent substantial pharmaceutical markets. This broad coverage enhances the global protection of Bayer's intellectual property in this therapeutic area.
Companies operating in the ILT3 inhibitor space, particularly those focusing on small molecule approaches, will need to carefully assess EA033323 as part of their freedom-to-operate analysis. The specific chemical space claimed by Bayer, defined by the imidazopyridine scaffold and its various substitutions, represents a protected area of research and development.
The patent landscape is active, with multiple entities pursuing ILT3 inhibition through diverse modalities, including small molecules and biologics. Bayer's EA033323 contributes to this complexity by claiming a specific class of small molecule inhibitors. Companies may seek to differentiate their own technologies by:
- Developing compounds outside the scope of Bayer's specific claims.
- Focusing on different therapeutic indications not covered by Bayer's use claims.
- Exploring alternative mechanisms of ILT3 modulation or targeting entirely different immunological pathways.
The strategic value of EA033323 for Bayer is its ability to block competitors from developing and commercializing compounds falling within its claimed scope for a defined period across multiple Eurasian countries. For other market participants, understanding the precise boundaries of these claims is critical for navigating R&D, investment, and potential licensing strategies.
Key Takeaways
- Eurasian Patent EA033323 by Bayer Intellectual Property GmbH claims imidazopyridine derivatives as ILT3 inhibitors.
- The patent covers specific compound structures, methods of synthesis, and therapeutic uses for diseases mediated by ILT3.
- The broad composition of matter claims establish a protected chemical space for Bayer.
- The ILT3 inhibitor landscape is competitive, with multiple companies developing both small molecule and antibody-based therapies.
- Companies must conduct thorough freedom-to-operate analyses to navigate around EA033323 and other relevant patents.
Frequently Asked Questions
-
What is the primary therapeutic area targeted by the compounds claimed in EA033323?
The primary therapeutic area targeted is diseases or conditions mediated by ILT3, including inflammatory, autoimmune, and potentially oncological conditions.
-
Does EA033323 claim specific drug names or only generic chemical structures?
EA033323 claims generic chemical structures through a general formula and further defines specific examples of these compounds, rather than specific drug names.
-
Which geographical regions are covered by Eurasian Patent Organization patents?
Eurasian Patent Organization patents cover a defined list of member states, which include countries such as Russia, Belarus, Kazakhstan, and others. The exact list of member states is maintained by the Organization.
-
Can a competitor develop an ILT3 inhibitor if it is chemically distinct from the imidazopyridines in EA033323?
Yes, if a competitor develops an ILT3 inhibitor that is chemically distinct and does not fall within the scope of Bayer's claims, and is not covered by other existing patents, they may be able to do so, subject to freedom-to-operate assessments.
-
What is the typical duration of patent protection for EA033323?
For Eurasian patents, the standard term of protection is 20 years from the filing date, provided that the annual renewal fees are paid. The filing date for EA033323 was October 25, 2018.
Citations
[1] Incyte Corporation. (n.d.). Incyte Pipeline. Retrieved from https://www.incyte.com/pipeline/ (Note: This is a general reference to a company's pipeline and not a specific patent citation for Incyte's ILT3 research. Specific patent numbers would require a dedicated search of Incyte's IP portfolio.)
